Effects of Aripiprazole on Cognition and Psychomotor Function in Schizophrenia: An Open-Study

Effects of Aripiprazole on Cognition and Psychomotor Function in Schizophrenia: An Open-Study - Effects of Aripiprazole in Schizophrenia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005581

Enrollment

Registered

2011-05-15

Start date

2011-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

Aripiprazole will be started at 12 mg/day and increased to his or her target dose that will be determined based on their current antipsychotic dose according to chlorpromazine equivalence while the pr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Diagnosis of schizophrenia (DSM-IV) (2) Currently being treated with antipsychotic drug(s) (3) Clinically stable defined as no change in CGI for the past 8 weeks.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Critical Flicker Fusion( CFF) Digit Symbol Substitution test (DSST)	—

Secondary

Measure	Time frame
The Global Assessment of Functioning(GAF) Clinical Global Impression(CGI) Drug Attitude Inventry-10(DAI-10)	—

Countries

Japan

Contacts

Public ContactFumio Saito

Minamihanno Hospital Administration Office

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026